WO2007041891A1 - Methods of separating catechins from green tea leaves - Google Patents

Methods of separating catechins from green tea leaves Download PDF

Info

Publication number
WO2007041891A1
WO2007041891A1 PCT/CN2005/001644 CN2005001644W WO2007041891A1 WO 2007041891 A1 WO2007041891 A1 WO 2007041891A1 CN 2005001644 W CN2005001644 W CN 2005001644W WO 2007041891 A1 WO2007041891 A1 WO 2007041891A1
Authority
WO
WIPO (PCT)
Prior art keywords
catechins
egcg
converted
green tea
separated
Prior art date
Application number
PCT/CN2005/001644
Other languages
French (fr)
Inventor
Tak-Hang Chan
Wai-Har Lam
Original Assignee
The Hong Kong Polytechnic University
Mcgill University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Hong Kong Polytechnic University, Mcgill University filed Critical The Hong Kong Polytechnic University
Priority to CN2005800520132A priority Critical patent/CN101316830B/en
Priority to PCT/CN2005/001644 priority patent/WO2007041891A1/en
Publication of WO2007041891A1 publication Critical patent/WO2007041891A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/82Theaceae (Tea family), e.g. camellia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/60Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
    • C07D311/62Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2 with oxygen atoms directly attached in position 3, e.g. anthocyanidins

Definitions

  • This invention relates to methods of separating catechins from green tea leaves.
  • Green tea contains many constituents, including polyphenols which are commonly known as catechins. Catechins are thought to be responsible for many of the biological effects of tea. Some major components of green tea polyphenols are (-)-epzgallocatechin-3- gallate (EGCG), (-)-ep/gallocatechin (EGC), e/?/catechin-3-gallate (ECG) and (-)-epZcatechin (EC). In particular, (-)-EGCG, the most abundant catechin, has been found to have anticancer, antibacterial, antiviral, and a beneficial effect on cholesterol level in blood.
  • EGCG epigallocatechin-3- gallate
  • ECG e/?/catechin-3-gallate
  • EC epZcatechin
  • (-)-EGCG the most abundant catechin, has been found to have anticancer, antibacterial, antiviral, and a beneficial effect on cholesterol level in blood.
  • Green tea Although the other catechins in green tea were found to be less effective in the above applications compared to EGCG, they may have other biological activities as well, and increasing their availability may assist in discovering such activities. Green tea also contains other components such as caffeine, proanthocyanidins, carbohydrates, amino acids and soluble minerals which are soluble in water together with the catechins in green tea infusions.
  • the method provides (-)-EGCG of 75% to 97% purity.
  • the recovery of (-)-EGCG from the green tea extract was only about 73%, and the process is considered to be not efficient.
  • the absence of a simple, efficient and inexpensive method of obtaining pure (-)-EGCG has hampered the evaluations of (-)-EGCG in animal and human clinical studies.
  • this invention provides a method of separating catechins from green tea leaves.
  • the catechins are first converted to corresponding ester forms to form a ester mixture, and then separated by suitable methods.
  • the catechins are converted to their respective peracetate forms. More preferably, the catechins are converted to corresponding peracetate forms by acetic anhydride.
  • the converted catechins may be separated by column chromatorgraphy, preferably eluted on silica gel by a mixture comprising hexane and ethyl acetate. More preferably, the hexane and the ethyl acetate are in a ratio of 1 :2 v/v.
  • the ester mixture may first be filtered to obtain a filtrate before the converted catechins are separated. More preferably, the filtrate may then be washed by water, dried and then concentrated before the converted catechins are separated.
  • the converted catechins may be converted back to the catechins, preferably by a methanol solution of ammonium acetate.
  • the catechins that may be separated by the method of this invention may include of (- )-e/?z ' gallocatechin-3-gallate, (-)-epzgallocatechin, e/7/catechin-3-gallate and (-)-epZcatechin.
  • Figure 1 shows a scheme of a preferred embodiment of the separation method of this invention.
  • Figure 2 shows the X-ray diffraction crystal structure of (-)-EGC hexaacetate (2).
  • the catechins in crude green tea extracts may be separated relatively easily after the catechins are converted to their respective ester forms.
  • the converted catechins may then be separated.
  • Column chromatography is one of the widely used separation methods. Without any proof at this stage, it is believed that the conversion of the catechins into their respective ester forms may enhance the differentiation of the physical properties of the catechins towards, for example, the stationary support used during chromatographic separation.
  • the catechins may be converted to various different ester forms. Although it is possible to only convert a portion of the hydroxide groups on the catechins into ester forms, it is preferable to have all of the hydroxide groups converted to a single type of ester group. Firstly, this reduces the complexity of the later separation. Additionally, it is more economical.
  • the catechins are converted to their respective peracetate forms by excess amount of acetic anhydride. It should be noted that other ester forms, for example perbenzoate form, may be used.
  • the catechins may be converted to their respective peracetate forms using any suitable methods, for example using acetyl chloride instead of acetic anhydride.
  • the catechins may also be converted to ether forms, this is not desirable as the vigorous reaction conditions involved, either converting the catechins into the ester forms or re-converting the esters back into the catechins, may destroy the catechins themselves.
  • FIG. 1 shows a scheme of a preferred embodiment of the separation method of this invention.
  • the catechins in the green tea leaves are first converted to their peracetate forms.
  • Direct application of esterification agent, for example acetic anhydride, to the green tea leaves may achieve this purpose.
  • crude green tea extracts may first be obtained by putting green tea leaves in hot water, and the hot water extract may be dried then react with the esterification agent.
  • this may be less desirable as this extra extraction step may reduce the overall extraction efficiency.
  • the converted catechins are then separated by traditional column chromatography.
  • the eluent may be a mixture comprising hexane and ethyl acetate, preferably in a ration of 1 :2 v/v.
  • the peracetated mixture may first be filtered before the converted catechins are separated by chromatography.
  • the filtrate may then be washed by water, dried and then concentrated by evaporation.
  • catechins After the catechins are separated in their respective ester forms, they may then be converting catechins by, for example, using a methanol solution of ammonium acetate.
  • catechins including (-)-e/>zgallocatechin-3- gallate, (-)-epz ' gallocatechin, e/?/catechin-3-gallate and (-)-epzcatechin may be separated from green tea extracts.
  • Mee green tea leaves were purchased from Ying Kee Tea House, Hong Kong. All reagents and solvents from purchased from commercial suppliers and were used without further purification unless otherwise specified. Ammonium acetate was dried under reduced pressure before use. The water used in HPLC was doubly de-ionized water. 1 H and ' 3 C NM R spectra were determined with a Varian-500 NMR spectrometer. Low and high resolution mass spectra were recorded on a Finnigan Model Mat 95 ST mass spectrometer, using positive ion electrospray ionization techniques. Melting point determinations were recorded on a B ⁇ chi Melting Point B-545 instrument and were uncorrected.
  • Thin layer chromatography was performed on Merck pre-coated silica gel 60 F254 plates and was viewed under a 254 nm lamp.
  • Silica gel (Merck, 230-400 mesh) was used for column chromatography.
  • HPLC was conducted on a HP 1100 liquid chromatograph, equipped with a C- 18 reverse phase column (CAPCELL PAK C18 UG 120, 4.6 mm i.d. x 250 mm).
  • the crude 1 was dissolved in ethyl acetate and filtered through a layer of activated charcoal (1 cm width x 3 cm long) to give pure (-)-EGCG peracetate (1) as a white solid (0.19 g, 4.3% yield) after evaporation.
  • (-)-EGC hexaacetate (2) was also isolated from column chromatography (hexane: ethyl acetate 1 :2, R f value is 0.6) and was filtered through a layer of activated charcoal. The crude compound 2 was recrystallized from dichloromethane: diethyl ether: hexane (1 :2:0.5) to give pure EGC hexaacetate 2 as white solid (0.07 g, 1.5% yield).
  • Green tea leaves (83.2 g, purchased from SElYU) was added to a mixture of pyridine (160 mL) and acetic anhydride (80 niL). The resulting mixture was stirred at room temperature for overnight. The solvent was removed under reduced pressure. Then the mixture was filtered with a sintered glass funnel and washed with ethyl acetate (100 mL x 5). The filtrate was washed with water (100 mL x 5) and brine solution (20 mL). The organic phase was dried over MgSO 4 , filtered and evaporated by rotary evaporator.
  • Green tea leaves (26.9g) (Shou Mee) were ground into powder.
  • the powder was added to acetic anhydride (3OmL), and pyridine (4OmL) in an ice-water bath. The resulting mixture was stirred for 12 hours at room temperature. Excess pyridine and acetic anhydride were then removed under reduced pressure (20 mmHg).
  • the mixture was filtered with a layer of silica gel and the filter cake was washed with ethyl acetate (5 x 10OmL).
  • the filtrate was washed with 0.1M HCl (5 x 10OmL), saturated sodium hydrogencarbonate solution (3 x 10OmL) and brine solution (200 niL).
  • the organic phase was dried over MgSO 4 and filtered.
  • the filtrate ( ⁇ 40mL) was evaporated by rotary evaporator.
  • the crude product was in foam- like form with dark green colour.
  • the crude product was purified by column chromatography (silica gel, 10 g) with n-hexane/ethyl acetate (1 :2 v/v) as the eluent.
  • the fractions containing the (-)-EGC hexaacetate (2) was collected and the solvents were evaporated to obtain the (-)-EGC hexaacetate with physical properties identical to an authentic sample.
  • the fractions containing the (-)-EC pentaacetate (3) was collected and the solvents were evaporated to obtain the (-)-EC pentaacetate with physical properties identical to an authentic sample.
  • the combined isolated yield of 2 and 3 was less than 0.5 %.
  • the ready available compound 1 allows its conversion to the precursor (-)-EGCG ammonium acetate in aqueous methanol to give (-)-EGCG in 90% yield as white crystals with identical NMR spectra as authentic sample:

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

There have been a number of reports on the isolation of (-)-EGCG from green tea. However, the presence of many components with their similar water solubility and the structural similarities of the catechins make the isolation of pure (-)-EGCG difficult. The absence of a simple, efficient and inexpensive method of obtaining pure (-)-EGCG has hampered the evaluations of (-)-EGCG in animal and human clinical studies. This invention provides a method of isolating catechins, including (-)-EGCG, by first converting the catechins to their respective ester forms. The esterified catechins are then separated by chromatography, and converted back to catechins. The method of this invention is relatively simple, and a substantial amount of catechins may be obtained.

Description

Methods of Separating Catechins from Green Tea Leaves
Field of the Invention
This invention relates to methods of separating catechins from green tea leaves.
Background of the Invention
Green tea contains many constituents, including polyphenols which are commonly known as catechins. Catechins are thought to be responsible for many of the biological effects of tea. Some major components of green tea polyphenols are (-)-epzgallocatechin-3- gallate (EGCG), (-)-ep/gallocatechin (EGC), e/?/catechin-3-gallate (ECG) and (-)-epZcatechin (EC). In particular, (-)-EGCG, the most abundant catechin, has been found to have anticancer, antibacterial, antiviral, and a beneficial effect on cholesterol level in blood. Although the other catechins in green tea were found to be less effective in the above applications compared to EGCG, they may have other biological activities as well, and increasing their availability may assist in discovering such activities. Green tea also contains other components such as caffeine, proanthocyanidins, carbohydrates, amino acids and soluble minerals which are soluble in water together with the catechins in green tea infusions.
There have been a number of reports on the isolation of (-)-EGCG from green tea. However, the presence of many components with similar water solubility and the structural similarities of the catechins make the isolation of pure (-)-EGCG difficult. US patent no. 6,210,679 describes a four-step process involving three column chromatographic separations to give eventually (-)-EGCG of 95-98% purity. Because of the need of using expensive reverse phase column fillings, the method is time consuming and not economical. US patent publication no. 20030083270 describes a process of providing (-)-EGCG by subjecting a green tea extract to chromatography on a macroporous polar resin with a polar elution solvent under pressure. The method provides (-)-EGCG of 75% to 97% purity. However, the recovery of (-)-EGCG from the green tea extract was only about 73%, and the process is considered to be not efficient. The absence of a simple, efficient and inexpensive method of obtaining pure (-)-EGCG has hampered the evaluations of (-)-EGCG in animal and human clinical studies. Objects of the Invention
Therefore, it is an object of this invention to provide methods for separating catechins from a green tea extract that involve relatively simple steps, and are preferably more efficient.
It is also an object of this invention to resolve at least one or more of the problems as set forth in the prior art. As a minimum, it is an object of this invention to provide the public with a useful choice.
Summary of the Invention
Accordingly, this invention provides a method of separating catechins from green tea leaves. The catechins are first converted to corresponding ester forms to form a ester mixture, and then separated by suitable methods.
Preferably, the catechins are converted to their respective peracetate forms. More preferably, the catechins are converted to corresponding peracetate forms by acetic anhydride.
The converted catechins may be separated by column chromatorgraphy, preferably eluted on silica gel by a mixture comprising hexane and ethyl acetate. More preferably, the hexane and the ethyl acetate are in a ratio of 1 :2 v/v.
Optionally, the ester mixture may first be filtered to obtain a filtrate before the converted catechins are separated. More preferably, the filtrate may then be washed by water, dried and then concentrated before the converted catechins are separated.
After the converted catechins are separated, they may be converted back to the catechins, preferably by a methanol solution of ammonium acetate.
The catechins that may be separated by the method of this invention may include of (- )-e/?z'gallocatechin-3-gallate, (-)-epzgallocatechin, e/7/catechin-3-gallate and (-)-epZcatechin. Brief description of the drawings
Preferred embodiments of the present invention will now be explained by way of example and with reference to the accompanying drawings in which:
Figure 1 shows a scheme of a preferred embodiment of the separation method of this invention; and
Figure 2 shows the X-ray diffraction crystal structure of (-)-EGC hexaacetate (2).
Detailed Description of the Preferred Embodiment
This invention is now described by way of example with reference to the figures in the following paragraphs.
Objects, features, and aspects of the present invention are disclosed in or are obvious from the following description. It is to be understood by one of ordinary skilled in the art that the present discussion is a description of exemplary embodiments only, and is not intended as limiting the broader aspects of the present invention, which broader aspects are embodied in the exemplary constructions.
According to this invention, it was surprisingly found that the catechins in crude green tea extracts may be separated relatively easily after the catechins are converted to their respective ester forms. The converted catechins may then be separated. Column chromatography is one of the widely used separation methods. Without any proof at this stage, it is believed that the conversion of the catechins into their respective ester forms may enhance the differentiation of the physical properties of the catechins towards, for example, the stationary support used during chromatographic separation.
The catechins may be converted to various different ester forms. Although it is possible to only convert a portion of the hydroxide groups on the catechins into ester forms, it is preferable to have all of the hydroxide groups converted to a single type of ester group. Firstly, this reduces the complexity of the later separation. Additionally, it is more economical. In the following examples, the catechins are converted to their respective peracetate forms by excess amount of acetic anhydride. It should be noted that other ester forms, for example perbenzoate form, may be used. Of course, the catechins may be converted to their respective peracetate forms using any suitable methods, for example using acetyl chloride instead of acetic anhydride. Although the catechins may also be converted to ether forms, this is not desirable as the vigorous reaction conditions involved, either converting the catechins into the ester forms or re-converting the esters back into the catechins, may destroy the catechins themselves.
Figure 1 shows a scheme of a preferred embodiment of the separation method of this invention. As shown in Figure 1, the catechins in the green tea leaves are first converted to their peracetate forms. Direct application of esterification agent, for example acetic anhydride, to the green tea leaves may achieve this purpose. Alternatively, crude green tea extracts may first be obtained by putting green tea leaves in hot water, and the hot water extract may be dried then react with the esterification agent. However, this may be less desirable as this extra extraction step may reduce the overall extraction efficiency. The converted catechins are then separated by traditional column chromatography. The eluent may be a mixture comprising hexane and ethyl acetate, preferably in a ration of 1 :2 v/v.
To further enhance the efficiency of the separation method of this invention, the peracetated mixture may first be filtered before the converted catechins are separated by chromatography. The filtrate may then be washed by water, dried and then concentrated by evaporation.
After the catechins are separated in their respective ester forms, they may then be converting catechins by, for example, using a methanol solution of ammonium acetate.
According to the method of this invention, catechins including (-)-e/>zgallocatechin-3- gallate, (-)-epz'gallocatechin, e/?/catechin-3-gallate and (-)-epzcatechin may be separated from green tea extracts.
Examples General Green tea packs were purchased from SEIYU with OSK trademark. Alternately, Shou
Mee green tea leaves were purchased from Ying Kee Tea House, Hong Kong. All reagents and solvents from purchased from commercial suppliers and were used without further purification unless otherwise specified. Ammonium acetate was dried under reduced pressure before use. The water used in HPLC was doubly de-ionized water. 1H and '3C NM R spectra were determined with a Varian-500 NMR spectrometer. Low and high resolution mass spectra were recorded on a Finnigan Model Mat 95 ST mass spectrometer, using positive ion electrospray ionization techniques. Melting point determinations were recorded on a Bϋchi Melting Point B-545 instrument and were uncorrected. Thin layer chromatography was performed on Merck pre-coated silica gel 60 F254 plates and was viewed under a 254 nm lamp. Silica gel (Merck, 230-400 mesh) was used for column chromatography. HPLC was conducted on a HP 1100 liquid chromatograph, equipped with a C- 18 reverse phase column (CAPCELL PAK C18 UG 120, 4.6 mm i.d. x 250 mm).
Isolation of individual catechins from green tea leaves from SEIYU
Pyridine (12 mL) and acetic anhydride (8 mL) were added to green tea leaves (4.55 g, purchased from SEIYU) in a round bottom flask. The mixture was stirred at room temperature overnight. Then it was dried under vacuum. The reaction mixture was washed with ethyl acetate (20 mL x 4) and filtered. The filtrate was washed with water (20 mL x 4). The filtrate was dried over sodium sulfate and evaporated. The crude product was purified by column chromatography over silica gel using «-hexane:ethyl acetate (v:v=l :2) as eluent to afford the crude (-)-EGCG peracetate 1 (Rf value was 0.3, green color). The crude 1 was dissolved in ethyl acetate and filtered through a layer of activated charcoal (1 cm width x 3 cm long) to give pure (-)-EGCG peracetate (1) as a white solid (0.19 g, 4.3% yield) after evaporation. Besides 1, (-)-EGC hexaacetate (2) was also isolated from column chromatography (hexane: ethyl acetate 1 :2, Rf value is 0.6) and was filtered through a layer of activated charcoal. The crude compound 2 was recrystallized from dichloromethane: diethyl ether: hexane (1 :2:0.5) to give pure EGC hexaacetate 2 as white solid (0.07 g, 1.5% yield).
(-)-EGCG peracetate (1): Mp 1 12.4-1 13.8 °C (compared with the one synthesized from commercially available (-)-EGCG, 1 15 0C); [α]D -67.7 (c 1.0, CHCl3); 1H NMR (CDCl3, 500MHz): 67.62 (s, 2H), 7.23 (s, 2H), 6.73 (d, J=2.5 Hz, IH), 6.61 (d, J=2.5 Hz, IH), 5.63 (br s, IH), 5.18 (s, IH), 3.02 (m, 2H), 2.28 (s, 3H), 2.27 (s, 9H), 2.26 (s, 3H), 2.24 (s, 3H), 2.22 (s, 6H); 13C NMR (125 MHz, CDCl3): δ 168.89, 168.40, 167.59, 167.43, 166.72, 166.20, 163.51, 154.71, 149.72, 149.64, 143.38, 143.29, 138.93, 135.06, 134.34, 127.41 , 122.34, 1 18.79, 109.42, 109.00, 108.06, 76.46, 67.98, 25.85, 21.06, 20.75, 20.54, 20.1 1 ; LRMS m/z (ESI) 817 [M+Na]+; HRMS: Calcd for C38H34Oi9Na, 817.1592; found, 817.1586. (-)-EGC hexaacetate (2): Mp 189.5-191.2 °C; [α]D -14.6 (c=1.0, CHCl3); 1H NMR (CDCl3, 500MHz): 67.22 (s, 2H), 6.67 (d, J=2.0 Hz, IH), 6.57 (d, J=2.0 Hz, IH), 5.38 (br s, IH), 5.08 (s, IH), 2.93 (m, 2H), 2.29 (s, 6H), 2.28 (s, 6H), 2.28 (s, 3H), 1.94 (s, 3H); 13C NMR (CDCl3, 120MHz): δ 170.58, 169.06, 168.50, 167.72, 166.90, 154.80, 149.73, 149.69, 143.26, 135.48, 134.28, 119.01, 109.56, 108.86, 108.08, 76.49, 66.44, 25.95, 21.10, 20.80, 20.77, 20.69, 20.19: LRMS m/z (ESI):581 [M+Na]+; HRMS: Calcd for C27H26O13Na, 581.1271 ; found, 581.1252.
Larger scale isolation ofcatechin acetates from green tea leaves from SEIYU
Green tea leaves (83.2 g, purchased from SElYU) was added to a mixture of pyridine (160 mL) and acetic anhydride (80 niL). The resulting mixture was stirred at room temperature for overnight. The solvent was removed under reduced pressure. Then the mixture was filtered with a sintered glass funnel and washed with ethyl acetate (100 mL x 5). The filtrate was washed with water (100 mL x 5) and brine solution (20 mL). The organic phase was dried over MgSO4, filtered and evaporated by rotary evaporator. The crude product was purified by column chromatography over silica gel with w-hexane/ethyl acetate (v:v=l:2) as eluent. Three columns (25 x 6 cm i. d., 25 x 6 cm i.d. and 24 x 3.5 cm i.d. respectively, with 3 cm of activated charcoal loaded on the top of the third column) were used. The crude products were chromatographed over these columns and fractions collected with TLC analysis using n-hexane/ethyl acetate (v:v=l :2) as eluent. The fractions containing the compound with Rf value of 0.32 were combined and evaporated to give (-)-EGCG peracetate (1) as a white solid (2.83 g, 3.4% yield). The fractions containing the compound with Rf value of 0.46 were combined and evaporated to give (-)-ECG heptaacetate (4). This was followed by the fractions containing the compound with Rf value of 0.58 which was evaporated to give (-)-EGC hexaacetate (2) (0.92 g, 1.1% yield). Finally, the fractions containing the compound with Rf value of 0.68 were also combined and evaporated to give the (-)-EC pentaacetate (3). The yields of compounds 3 and 4 were less than 0.01%.
EC pentaacetate (3): 1H NMR (CDCl3, 500MHz): 57.22 (m, 3H ), 6.67 (s, IH), 6.57 (s, IH), 5.38 (br s. I H), 5.08 (s, IH), 2.94 (m, 2H), 2.29 (m, 15H); HRMS (ESI): Calcd for C25H24On Na (M+Na)+ 523,1216, found, 523.1198. ECG heptaacetate (4): 1H NMR (CDCl3, 500MHz): 67.62 (s, 2H), 7.25 (m, 3H), 6.73 (s, IH), 6.60 (s, IH), 5.63 (br s, I H), 5.20 (s, IH), 3.06 (m, 2H), 2.27 (m, 21H); HRMS (ESI): Calcd for C36H32O17Na (M+Na)+ 759.1537, found, 759.1515.
Isolation of individual catechins from Shou Mee green tea leaves
Green tea leaves (26.9g) (Shou Mee) were ground into powder. The powder was added to acetic anhydride (3OmL), and pyridine (4OmL) in an ice-water bath. The resulting mixture was stirred for 12 hours at room temperature. Excess pyridine and acetic anhydride were then removed under reduced pressure (20 mmHg). The mixture was filtered with a layer of silica gel and the filter cake was washed with ethyl acetate (5 x 10OmL). The filtrate was washed with 0.1M HCl (5 x 10OmL), saturated sodium hydrogencarbonate solution (3 x 10OmL) and brine solution (200 niL). The organic phase was dried over MgSO4 and filtered. The filtrate (~40mL) was evaporated by rotary evaporator. The crude product was in foam- like form with dark green colour. The crude product was purified by column chromatography (silica gel, 10 g) with n-hexane/ethyl acetate (1 :2 v/v) as the eluent.
The fractions containing the (-)-EGCG peracetate (1) was collected and the solvents were evaporated to obtain the (-)-EGCG peracetate. (1.25g, 4.6%) with physical and spectroscopic properties identical to authentic sample.
The fractions containing the (-)-ECG heptaacetate (4) was collected and the solvents
120 were evaporated to obtain the (-)-ECG heptaacetate. (0.24g, 0.88%): Mp 104 - HOO ; [afL
57.6 (c = 0.60, CHCl3); 1H NMR (CDCl3, 400MHz) δ 7.62 (s, 2H), 7.29-7.33 (m, 2H), 7.21 (s, IH), 6.73 (d, J= 2.2Hz, IH), 6.60 (d, J= 2.1Hz, IH), 5.63 (s, IH), 5.20 (s, IH), 3.08 (dd, J = 17.9, 4.6Hz, IH), 2.98 (dd, J = 17.9, 2.0Hz, IH), 2.14-2.29 (m, 21H); 13C NMR (CDCl3, 100MHz) δ 168.9, 168.4, 168.0, 167.9, 167.4, 166.2, 163.5, 154.9, 149.7, 143.3, 142.1 , 142.0, 138.9, 135.4, 127.4, 124.4, 123.5, 122.3, 121.8, 118.7, 109.5, 108.9, 108.0, 76.7, 68.1, 25.9, 21.1, 20.7, 20.5, 20.1; LRMS (ESI) m/∑ 759 ([M+Na]+, 66), 737 ([M+H]+, 42); HRMS calcd for C36H32OnNa 759.1537, found 759.1508.
The fractions containing the (-)-EGC hexaacetate (2) was collected and the solvents were evaporated to obtain the (-)-EGC hexaacetate with physical properties identical to an authentic sample. The fractions containing the (-)-EC pentaacetate (3) was collected and the solvents were evaporated to obtain the (-)-EC pentaacetate with physical properties identical to an authentic sample. The combined isolated yield of 2 and 3 was less than 0.5 %.
Procedure for the synthesis of (-)-EGCG from (-)-EGCG per acetate (1)
NH4OAc (4.3 g, 56 mmol) was added to (-)-EGCG peracetate 1 (350 mg, 0.42 mmol) and vitamin C (35 mg) in MeOHiH2O (4:1) (20 mL) at room temperature. The resulting mixture was stirred at 40 °C until 1 disappeared and EGCG was formed (reaction progress was monitored with HPLC: C-18 reverse phase column; flow rate, 1 mL/min; detection, UV 280 nm; mobile phase, 0-8 min (20% aqueous acetonitrile and 0.016% TFA), 8-13 min (varying from 20% aqueous acetonitrile with 0.016% TFA to 60% aqueous acetonitrile with 0.008% TFA). The reaction mixture was dried under vacuum. Water was added and the mixture was extracted with ethyl acetate (8 mL x 3). The filtrate was then dried over sodium sulfate and evaporated. The crude product was purified by column chromatography over silica gel (ethyl acetate, Rf value was 0.5) to afford the EGCG (180 mg, 90% yield) as off white solid. Its identity with an authentic sample of (-)-EGCG was confirmed by NMR spectroscopy and other physical data.
Determination of Crystal structure
The crystal structure of compound 2 was determined by the direct method on a Bruker CCD area detector diffractometer using MoK (λ radiation = 0.71073 A) from generator operating at 50KV, 30mA condition. The positions of part of non-hydrogen atoms and subsequent difference Fourier syntheses were employed to locate all of the remaining non- hydrogen atoms which did not show up in the initial structure. All of non-hydrogen atoms were refined anisotropically. Hydrogen atoms were located basing on difference Frouier Syntheses connecting geometrical analysis. All experiment and computation were performed on a pc computer with program of Bruker Smart and Bruker Shelxtl package. The crystal structure of 2 is shown in Figure 2.
Results and Discussion
Green tea leaves were treated with acetic anhydride and pyridine directly at room temperature overnight. All the catechins, including (-)-EGCG, were presumably converted to the corresponding acetates (Figure 1 ) as excess amount of acetic anhydride was used. The reaction mixture was then extracted with ethyl acetate and filtered. The catechin acetates were then separated from each other by simple column chromatography on silica gel with hexane:ethyl acetate (1 :2 v/v) to give pure crystalline EGCG peracetate (1) as the major product in 3.4 - 4.6% dry weight of the green tea leaves. The EGC hexaacetate (2) was also obtained as crystals in 1.1 -1.5% dry weight. Compound 1 thus isolated was identical in all respects with the sample synthesized previously. The structure of compound 2, in addition to being consistent with the spectroscopic data, was confirmed by crystallographic determination with X-ray diffraction (Figure 2). In addition to the isolation of 1 and 2, small amounts of (-)-EC pentaacetate (3) and (-)-ECG heptaacetate (4) were also isolated. There is marked contrast between the ease of separation of the different catechin acetates 1-4 and the difficulty in the separation of the catechins with their free phenolic groups by normal phase silica gel chromatography.
The ready available compound 1 allows its conversion to the precursor (-)-EGCG ammonium acetate in aqueous methanol to give (-)-EGCG in 90% yield as white crystals with identical NMR spectra as authentic sample:
Figure imgf000010_0001
The use of (-)-EGCG peracetate (1) and other catechin acetates as prodrugs for proteasome inhibition and apoptosis inducers of human cancer cells is described. [D. Kuhn, W. H. Lam, A. Kazi, K. G. Daniel, S. Song, L. M. C. Chow, T. H. Chan, Q. P. Dou, Synthetic peracetate polyphenols as potent proteasome inhibitors and apoptosis inducers in human cancer cells, Frontiers in Bioscience, 10, 1010-1023 (2005); W. H. Lam, A. Kazi, D. J. Kuhn, L. M. C. Chow, A. S. C. Chan, Q. P. Dou, T. H. Chan, A potential prodrug for a green tea polyphenol proteasome inhibitor: evaluation of the peracetate ester of (-)-epigallocatechin gallatc [(-)-EGCG], Bioorg. Med. Chem., 12, 5587-5593 (2004).] These ester derivatives are usually prepared from the esterifϊcation of the pure (-)-EGCG or other catechins. The absence of a simple, efficient and inexpensive method of obtaining pure (-)-EGCG or other catechins has also hampered the preparation of (-)-EGCG peracetate (1) and the evaluations of 1 or other catechin ester derivatives in animal and human clinical studies. Using the method of this invention, catechins in green tea extracts can become more readily available. This may facilitate the biological viability studies of this compounds .
While the preferred embodiment of the present invention has been described in detail by the examples, it is apparent that modifications and adaptations of the present invention will occur to those skilled in the art. Furthermore, the embodiments of the present invention shall not be interpreted to be restricted by the examples or figures only. It is to be expressly understood, however, that such modifications and adaptations are within the scope of the present invention, as set forth in the following claims. For instance, features illustrated or described as part of one embodiment can be used on another embodiment to yield a still further embodiment. Thus, it is intended that the present invention cover such modifications and variations as come within the scope of the claims and their equivalents.

Claims

CLAIMS:
1. A method of separating catechins from green tea leaves, including the steps of: converting the catechins to corresponding ester forms to form a ester mixture; separating the converted catechins in the ester mixture.
2. The method of claim 1, wherein the catechins are converted to their respective peracetate forms.
3. The method of claim 2, wherein the catechins are converted to corresponding peracetate forms by acetic anhydride.
4. The method of claim 1, wherein the converted catechins are separated by column chromatorgraphy.
5. The method of claim 4, wherein the converted catechins are eluted on silica gel by a mixture comprising hexane and ethyl acetate.
6. The method of claim 5, wherein the hexane and the ethyl acetate are in a ratio of 1 :2 v/v.
7. The method of claim 1 further including the step of filtering the ester mixture to obtain a filtrate before the converted catechins are separated.
8. The method of claim 7 further including the step of washing the filtrate by water, drying the filtrate and then concentrating the filtrate before the converted catechins are separated.
9. The method of claim 1 further including the step of converting the converted catechins back to the catechins after being separated.
10. The method of claim 9, wherein the converted catechins back to the catechins by a methanol solution of ammonium acetate.
11. The method of claim 1 , wherein the catechins is selected from the group consisting of (-)-ep/gallocatechin-3-gallate, (-)-e/?/gallocatechin, epj'catechin-3-gallate and (-)- e/7/catechin.
PCT/CN2005/001644 2005-10-08 2005-10-08 Methods of separating catechins from green tea leaves WO2007041891A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN2005800520132A CN101316830B (en) 2005-10-08 2005-10-08 Method for separating catechin from green tea
PCT/CN2005/001644 WO2007041891A1 (en) 2005-10-08 2005-10-08 Methods of separating catechins from green tea leaves

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2005/001644 WO2007041891A1 (en) 2005-10-08 2005-10-08 Methods of separating catechins from green tea leaves

Publications (1)

Publication Number Publication Date
WO2007041891A1 true WO2007041891A1 (en) 2007-04-19

Family

ID=37942285

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2005/001644 WO2007041891A1 (en) 2005-10-08 2005-10-08 Methods of separating catechins from green tea leaves

Country Status (2)

Country Link
CN (1) CN101316830B (en)
WO (1) WO2007041891A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008153938A2 (en) * 2007-06-06 2008-12-18 University Of South Florida Epigallocatechin-3-gallate crystal compositions
WO2011128714A1 (en) * 2010-04-12 2011-10-20 Berkem S.A. Stabilised polyphenol derivatives, process for their manufacture, and uses thereof
CN109053668A (en) * 2018-07-25 2018-12-21 云南茶农生物产业有限责任公司 A method of ester catechin is prepared with tea polyphenols
US10376521B2 (en) 2007-06-06 2019-08-13 University Of South Florida Nutraceutical co-crystal compositions
CN111250068A (en) * 2020-01-21 2020-06-09 中华全国供销合作总社杭州茶叶研究所 Application and method of acetylation medium filler for separating and purifying tea catechin
US11420954B2 (en) 2017-12-05 2022-08-23 Crystalmorphix Technologies Pvt. Ltd Process for the separation of gallated epicatechins (EGCG and ECG) from green tea extract or green tea dust

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102875691B (en) * 2012-10-19 2015-02-25 黄冈师范学院 Method for synchronously preparing active substances from tea dregs

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55105677A (en) * 1979-02-07 1980-08-13 Norin Suisansyo Chiyagiyou Shikenjo Production of catechins
JPS5695182A (en) * 1980-12-18 1981-08-01 Norin Suisansyo Chiyagiyou Shikenjo Production of catechin
JPH0770105A (en) * 1993-08-26 1995-03-14 Shokuhin Sangyo High Separeeshiyon Syst Gijutsu Kenkyu Kumiai Production of tea catechins
CN1603319A (en) * 2004-07-30 2005-04-06 合肥工业大学 Separation purification method of catechin monomer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55105677A (en) * 1979-02-07 1980-08-13 Norin Suisansyo Chiyagiyou Shikenjo Production of catechins
JPS5695182A (en) * 1980-12-18 1981-08-01 Norin Suisansyo Chiyagiyou Shikenjo Production of catechin
JPH0770105A (en) * 1993-08-26 1995-03-14 Shokuhin Sangyo High Separeeshiyon Syst Gijutsu Kenkyu Kumiai Production of tea catechins
CN1603319A (en) * 2004-07-30 2005-04-06 合肥工业大学 Separation purification method of catechin monomer

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008153938A2 (en) * 2007-06-06 2008-12-18 University Of South Florida Epigallocatechin-3-gallate crystal compositions
WO2008153938A3 (en) * 2007-06-06 2009-02-19 Univ South Florida Epigallocatechin-3-gallate crystal compositions
US8471044B2 (en) 2007-06-06 2013-06-25 University Of South Florida Epigallocatechin-3-gallate crystal compositions
US10376521B2 (en) 2007-06-06 2019-08-13 University Of South Florida Nutraceutical co-crystal compositions
US10842797B2 (en) 2007-06-06 2020-11-24 University Of South Florida Nutraceutical co-crystal compositions
WO2011128714A1 (en) * 2010-04-12 2011-10-20 Berkem S.A. Stabilised polyphenol derivatives, process for their manufacture, and uses thereof
JP2013528574A (en) * 2010-04-12 2013-07-11 ベルケム エス.ア. Stabilized polyphenol derivatives, production method thereof, and use thereof
US11420954B2 (en) 2017-12-05 2022-08-23 Crystalmorphix Technologies Pvt. Ltd Process for the separation of gallated epicatechins (EGCG and ECG) from green tea extract or green tea dust
CN109053668A (en) * 2018-07-25 2018-12-21 云南茶农生物产业有限责任公司 A method of ester catechin is prepared with tea polyphenols
CN111250068A (en) * 2020-01-21 2020-06-09 中华全国供销合作总社杭州茶叶研究所 Application and method of acetylation medium filler for separating and purifying tea catechin
CN111250068B (en) * 2020-01-21 2022-10-18 中华全国供销合作总社杭州茶叶研究所 Application and method of acetylation medium filler for separating and purifying tea catechin

Also Published As

Publication number Publication date
CN101316830B (en) 2012-01-25
CN101316830A (en) 2008-12-03

Similar Documents

Publication Publication Date Title
WO2007041891A1 (en) Methods of separating catechins from green tea leaves
AU2001266885B2 (en) An improved method for extracting cocoa procyanidins
Matsuura et al. Isolation of α-glusosidase inhibitors from hyssop (Hyssopus officinalis)
Miyano et al. Asymmetric synthesis of axially dissymmetric 1, 1'-binaphthyls via an intramolecular Ullmann coupling reaction of (R)-and (S)-2, 2'-bis (1-bromo-2-naphthylcarbonyloxy)-1, 1'-binaphthyl.
Zeng et al. Bioactive phenolics from the fruits of Livistona chinensis
JP5597142B2 (en) Sulfated C-glycoside, isolation method and synthesis method thereof
JPH03170495A (en) Preparation of isoflavone
US20070237885A1 (en) Process for the isolation of limonoid glucosides from citrus
KR20000076073A (en) Sphingosine analogues
Shan et al. Elucidation of micromolecular phenylpropanoid and lignan glycosides as the main antioxidants of Ginkgo seeds
JP2004518705A (en) Method for isolating and purifying secoisolariciresinol diglycoside (SDG) from flax seed
WO2006058299A2 (en) Manufacture of limonoid compounds
JP2022543794A (en) Method for producing tetragalloyl glucose
Fatah et al. Antioxidants and α-glucosidase Inhibitors from Lactuca serriola L
Jia et al. Preparative isolation and structural characterization of sucrose ester isomers from oriental tobacco
Prajapati et al. Isolation and identification of bioactive compounds from the tuber of Brassica oleracea var. gongylodes
KR100742265B1 (en) A mass production method of brazilein from Caesalpinia sappan L.
WO2014077398A1 (en) Method for producing polyphenol
Seo et al. Isolation and identification of cinnamic acid amides as antioxidants from Allium fistulosum L. and their free radical scavenging activity
CN115724812A (en) Extraction and separation method and application of furan ester alkaloid in purslane
CN110903241A (en) Separation and purification method of water-soluble catechol tetrahydroisoquinoline alkaloid
Cha et al. Two new amino acid-sesquiterpene lactone conjugates from Ixeris dentata
KR20070074718A (en) Theanine extraction process from green tea
CN109824685B (en) Compound oleracene G in purslane, extraction and separation method and application thereof
RU2352554C1 (en) Method of obtaining 2,3,5,7,8-pentahydroxy-6-ethyl-1,4-naphtoquinone

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200580052013.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05806203

Country of ref document: EP

Kind code of ref document: A1